Inclusion Criteria:  18 years or older Newly referred at the study site HIV-1 infected (fourth generation HIV Ag/Ab combination assay) Treatment-naïve to all anti-HIV therapy, except for the use for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), up to one month prior to screening Estimated GFR >30 mL/min/1.73m2 according to the Cockcroft-Gault formula for creatinine clearance Must be willing and able to understand the requirements of study participation and provide signed and dated written informed consent prior to screening Female participants who are willing to use acceptable methods of birth control as defined in the protocol  Exclusion Criteria:  Have received anti-HIV therapy previously, except for PrEP or PEP taken up to one month prior to screening Viral load <100 copies/mL, high suspicion of non-reported ART use or being a long-term nonprogressor or elite controller Concomitant use of drugs with contraindication or drug-drug interactions with B/F/TAF Documented historic or baseline allergy to any of the components of B/F/TAF Estimated eGFR (by Cockcroft-Gault formula) < 30 mL/min Pregnant, breast-feeding or planning or suspected to get pregnant Involvement in any other interventional HIV studies during the study period Has any reason, in the opinion of the investigator, which would make the candidate inappropriate for participation in an investigative study involving oral medications